BC Innovations | May 28, 2019
Distillery Therapeutics

Adrenergic receptor inhibitor combo to treat stroke

DISEASE CATEGORY: Neurology INDICATION: Stroke Mouse studies suggest inhibiting ADRA1, ADRA2 and ADRB could help treat acute ischemic stroke. In two mouse models of ischemic stroke, the combination of the ADRA1 antagonist prazosin, the ADRA2...
BC Week In Review | Jul 20, 2015
Clinical News

Dexmedetomidine: Phase II data

Top-line data from the double-blind Phase II REC-14-013 trial in 168 patients undergoing a bunionectomy showed that 50 ug Dex-IN every 6 hours for 48 hours starting on postoperative day 1 met the primary endpoint...
BC Extra | Jul 18, 2015
Clinical News

Recro's Dex-IN meets in Phase II pain study

Recro Pharma Inc. (NASDAQ:REPH) gained $0.65 to $16.58 after it said Dex-IN met the primary endpoint of a Phase II trial to treat acute pain in patients undergoing bunionectomy. The intranasal formulation of dexmedetomidine, an...
BC Week In Review | Apr 20, 2015
Clinical News

Dexmedetomidine: Phase II ongoing

Recro reduced target enrollment to 170 patients from 200-250 in the double-blind Phase II REC-14-013 trial of intranasal Dex-IN after a prespecified interim analysis. The analysis was to allow for sample size adjustment to maintain...
BC Week In Review | Nov 10, 2014
Clinical News

Dex-IN: Phase II started

Recro began the double-blind, placebo-controlled Phase II REC-14-013 trial to evaluate 50 Ug Dex-IN every 6 hours for 48 hours starting on post-operative day 1 in about 200-250 patients undergoing bunionectomy. In September, Recro discontinued...
BC Week In Review | Oct 13, 2014
Company News

Hospira, Orion, Novartis neurology news

Orion, Hospira and Novartis' Sandoz Inc. and Sandoz Canada Inc. units amended a December 2013 agreement to allow Sandoz rights to immediately launch a generic version of Precedex dexmedetomidine. Under the original agreement, Sandoz had...
BC Week In Review | Sep 29, 2014
Clinical News

Dex-IN: Phase IIb discontinued

Recro discontinued the double-blind, placebo-controlled, U.S. Phase IIb REC-13-012 trial evaluating 35 and 50 Ug intranasal Dex-IN starting on post-operative day 0 in 68 patients undergoing bunionectomy after an interim analysis of the primary endpoint...
BC Week In Review | Sep 15, 2014
Company News

Hospira, Food and Drug Administration neurology news

The U.S. District Court for the District of Maryland sided with FDA in a suit challenging whether the agency could approve generic versions of a sedative so long as the generic labels do not include...
BC Extra | Sep 9, 2014
Company News

Court rules against Hospira on generic Precedex

The U.S. District Court for the District of Maryland sided with FDA in a suit challenging whether the agency could approve generic versions of a sedative so long as the generic labels do not include...
BC Week In Review | Sep 1, 2014
Company News

Hospira, Food and Drug Administration neurology news

Hospira filed suit against FDA in the U.S. District Court for the District of Maryland alleging that FDA’s decision to approve generic versions of Hospira’s Precedex dexmedetomidine so long as the labels for the generics...
Items per page:
1 - 10 of 36